Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

M. Shaman, Ahmed; C. Bain, Stephen; L. Bakris, George; B. Buse, John; Idorn, Thomas; W. Mahaffey, Kenneth; F.E. Mann, Johannes; A. Nauck, Michael; Rasmussen, Søren; Rossing, Peter; Ole Wolthers, Benjamin; Zinman, Bernard; Perkovic, Vlado

doi:10.1161/circulationaha.121.055459

Public

Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER

Published in Circulation • Dec 14, 2021

Authors:

Ahmed M. Shaman

Stephen C. Bain

George L. Bakris

Abstract

Background: We assessed the effect of once-weekly semaglutide and once-daily liraglutide on kidney outcomes in type 2 diabetes. Methods: Pooled (n=12 637) and by-trial data from SUSTAIN 6 (Trial to Evaluate Cardiovascular and Other Long-Term Outcomes With Semaglutide in Subjects With Type 2 Diabetes...

Subject

Semaglutide

Liraglutide

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!